News about

Amgen to Set Up JV in China – Analyst Blog

Tue, 14 May 2013 17:50:01 -0400

The JV, Amgen-Beta Pharmaceuticals Co., will focus on the commercialization of Amgen's colorectal cancer drug, Vectibix, in China.

Disappointing 1Q Earnings for IART – Analyst Blog

Fri, 10 May 2013 11:08:01 -0400

Integra posts disappointing earnings and revenue, product recall adversely affects financials.

Zacks #1 Rank Additions for Thursday – Tale of the Tape

Thu, 02 May 2013 09:44:01 -0400

Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Thursday

A lower stock price never turns a bad company into a good one

Wed, 27 Mar 2013 06:56:19 -0400

When it comes to portfolio moves, we're cold-blooded in our analysis.

The post A lower stock price never turns a bad company into a good one appeared first on Smarter Investing.

Covestor Ltd. is a registered investment advisor. Covestor licenses investment strategies from its Model Managers to establish investment models. The commentary here is provided as general and impersonal information and should not be construed as recommendations or advice. Information from Model Managers and third-party sources deemed to be reliable but not guaranteed. Past performance is no guarantee of future results. Transaction histories for Covestor models available upon request. Additional important disclosures available at http://site.covestor.com/help/disclosures. For information about Covestor and its services, go to http://covestor.com or contact Covestor Client Services at (866) 825-3005, x703.

Morning Market Losers

Wed, 05 Dec 2012 09:55:26 -0500

Chelsea Therapeutics International (NASDAQ: CHTP) shares dipped 29.07% to $1.2710 at 9:54 am. Chelsea Therapeutics' trailing-twelve-month ROE is -114.86%.

Mattress Firm Holding (NASDAQ: MFRM) shares lost 22.82% to $23.40. Mattress Firm lowered its adjusted earnings view for the full year.

TIBCO Software (NASDAQ: TIBX) dropped 20.61%

Why our investment time horizon is a long one

Thu, 20 Sep 2012 07:49:09 -0400

We are investing with a time frame of quarters and years in mind.

Why our investment horizon is long

Thu, 20 Sep 2012 07:49:09 -0400

We are investing with a time frame of quarters and years in mind.

Zacks #5 Rank Additions for Wednesday – Tale of the Tape

Wed, 25 Apr 2012 09:14:01 -0400

Here are 5 stocks added to the Zacks #5 Rank ("strong sell") List for Wednesday

Zacks #5 Rank Additions for Friday – Tale of the Tape

Fri, 20 Apr 2012 09:14:01 -0400

Here are 5 stocks added to the Zacks #5 Rank ("strong sell") List for Friday

Positive Rumors About Anika Therapeutics Circulate (ANIK)

Thu, 02 Jun 2011 11:18:54 -0400

Unconfirmed positive rumors circulating at Anika Therapeutics (Nasdaq: ANIK). Positive chatter circulates. This article may include mentions of rumors, chatter, or unconfirmed information.

Amgen’s rally boosts biotech sector

Fri, 11 Mar 2011 13:31:22 -0500

One analyst says the market is speculating that Medicare rates for one of Amgen’s top products will remain unchanged.

Human Genome rallies against biotech downturn

Thu, 10 Mar 2011 12:46:17 -0500

New FDA-approved lupus treatment rallies shares as large-cap drug makers fuel broader market declines.

Anika Therapeutics Looks To Continue Growth In 2010

Sun, 25 Apr 2010 02:23:23 -0400

With a market value sub-$100 million, Anika Therapeutics (NASDAQ:ANIK) is a hidden growth story in the biotech arena. Article comes courtesy of, Rx Investors. FINANCIALLY SOUND ANIK is trading at low valuations compared to other biotech companies. The company is currently trading at 22.5 X earnings, 2.4 X sales, and 3.97 X its [...]

Genzyme, Adolor lead as drug stocks move higher

Fri, 21 Aug 2009 11:04:00 -0400

Drug- and biotech-sector benchmarks move higher in tandem with the broader stock market, as Genzyme gain on an analyst upgrade.

Biotech shares gain; Anika zooms on drug approval

Thu, 20 Aug 2009 10:42:00 -0400

Drug stocks are a mixed early Thursday, with biotech shares gaining the most ground.